Original Source(s)
Related Content
FDA Approves Gedatolisib in Breast Cancer
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
-
2 min
Narrow DCIS Margins May Not Always Warrant Reexcision
An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.
July 20, 2026
-
6 min
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min